Cyproheptadine for prevention of delirium in critically ill patients
Phase 2
- Conditions
- Delirium.Sudden changes in patients’ behavioral and psychological conditions
- Registration Number
- IRCT201312203449N13
- Lead Sponsor
- Vice Chancellor for Research, Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Inclusion Criteria: Non-cardiac surgical patients who are admitted to ICU and are hospitalized in Intensive Care Unit (ICU) for at-least 7 days.
Exclusion Criteria
Patients with history of neurological diseases, psychiatric disorders, cyproheptadine hypersensitivity, active GI bleeding, glaucoma, urinary retention and arrhythmia will be excluded from the study.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of Delirium. Timepoint: At ICU admission and then daily for 7 days. Method of measurement: CAM-ICU Questionnaire.
- Secondary Outcome Measures
Name Time Method Severity of Delirium. Timepoint: At ICU admission and then daily for 7 days. Method of measurement: CAM-ICU Questionnaire.